The following information was obtained from the
California Department of Public Health, Radiologic Health Branch, via email:
University of California at Los Angeles (UCLA) reported a medical event had occurred on Friday, July 26, 2024, during a Y-90 Therasphere liver cancer treatment. Patient SPECT imaging performed on August 1, 2024, showed that all of the Y-90 activity was in the patient's stomach tissue rather than in the intended left lobe of the liver. The licensee reported that the dosage of Y-90 administered was in conformance with the written directive. UCLA is continuing to investigate to determine how the Y-90 Theraspheres ended up in the stomach tissue and will address the cause in their 15-day written report to the Radiologic Health Branch.
Per the licensee's documentation, a dosage of 0.77 GBq was delivered to the patient, with 0.74 GBq expected to go to the treatment site to result in a dose of 178.9 Gy to the treatment site.
California event number: 5010-080124
A Medical Event may indicate potential problems in a medical facility's use of radioactive materials. It does not necessarily result in harm to the patient.